Yarwood Jeremy sold $115K of NEOG

Yarwood Jeremy (Chief Scientific Officer) sold 9,051 shares of NEOGEN CORP (NEOG) at $12.67 ($0.11M total) on 2026-11-04.

Original reporting
SEC EDGAR · Yarwood Jeremy
Published Nov 4, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NEOG
Bearish
medium confidence
Mentioned
$NEOG
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NEOGBearishLow
01

Why it matters

The complete divestiture by a senior officer may be interpreted as a negative signal, but the modest size limits market reaction.

02

Market read

A small insider sell with no immediate price target; likely limited trading relevance.

03

What to watch

No other material news accompanies the filing; the market may already price insider activity.

Relevance 4/10Novelty 5/10Timing: today

Background

SEC Form 4 filing discloses insider transactions. Such filings are primary sources for insider activity.

Company-level read

Ticker impact

$NEOGBearishMedium confidence
Context

Chief Scientific Officer Yarwood Jeremy sold 9,051 shares for $114,676, leaving zero holdings.

Expected impact

likely slight downward pressure as investors price the insider sell

Evidence & confidence

The sale is small but represents a C-suite insider exiting completely, which can be viewed negatively by the market.

Market effects

Minimal impact on the broader biotech sector; the sale is company‑specific.

No regional effect.

Limited to investors tracking NEOG.

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Yarwood Jeremy

    Chief Scientific Officer of NEOGEN Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Neogen Chemicals Ltd (BOM:542665) (Q2 2027) Earnings Call Highlights: 42% Revenue

Neogen Chemicals (BOM:542665) reported Q2 2027 earnings, with a 42% revenue surge. The company guided FY27 battery chemicals revenue at INR 250-300 crore and FY28 at over INR 1,000 crore. Base chemicals guidance for FY27 was upgraded to over INR 1,100 crore. Net debt for FY28 is expected to be INR 1,300-1,500 crore. The company is benefiting from US demand shifts due to tax credits and has secured customer approvals for lithium electrolyte salts.

$NEOGHigh

Neogen Corporation announced that it had entered into a definitive agreement to sell its global Genomics business to Zoetis Inc

NEOGEN CORP (NEOG) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On March 2, 2026, Neogen Corporation (“ Neogen ”) announced that it had entered into a definitive agreement to sell its global Genomics business to Zoetis Inc. (“ Zoetis ”). This transaction is subject to customary closing conditions and regulatory approva